The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Roche’s published AI claims fall into four areas: sharper disease detection in Diagnostics, faster decoding of biological connections, more targeted drug development, and predictive features in its Accu-Chek SmartGuide blood-glucose product. The company presents these as its strategy and its reasoning, not as measured results. Its 2024 and 2025 reporting does not quantify how much AI has changed patient outcomes, development timelines or revenue. So what Roche has established is where it believes AI fits and why it thinks its group structure helps; the measured effects are not shown in the material it has published.
What Roche says AI is for
Roche’s strategy combines its Diagnostics and Pharmaceuticals divisions, with digital products intended to support patients across prevention, screening, diagnosis, treatment and monitoring. The stated goal is to prevent, stop and cure diseases while improving outcomes and reducing costs for patients and health systems. Its focus areas are oncology, neurology, and cardiovascular and metabolic diseases. Roche also says its autonomous research and development centres and its alliances with more than 250 external partners are enhanced by AI. The company’s current strategy page sets out this framework.
As an Amazon Associate I earn from qualifying purchases.
The clearest statement of the company’s position comes from CEO Dr Thomas Schinecker’s 2024 letter to shareholders: “AI decodes complex biological connections faster, makes diagnostics more precise, facilitates more targeted drug development and much more.” Read it as a description of intent and potential. It is not a quantified evaluation of what AI has delivered. The letter is in Roche’s Annual Report 2024.
Four use cases at a glance
| Use case | Stage of care or development | What Roche says | Source and type of claim | Measured result reported |
|---|---|---|---|---|
| Diagnostic detection | Screening and diagnosis | AI algorithms in Diagnostics sharpen disease detection | 2025 annual review; company statement | Not stated |
| Biological insight | Research | AI decodes complex biological connections faster | 2024 CEO letter; company statement | Not stated for AI |
| Targeted drug development | Treatment development | AI facilitates more targeted drug development | 2024 CEO letter; company statement | Not stated |
| Predictive glucose features (Accu-Chek SmartGuide) | Monitoring | AI helps predictive features detect dangerous blood-glucose fluctuations earlier, so people can act in time | 2024 CEO letter; company-reported example | Not stated; no comparative performance data in the cited material |
How each use case works, and what backs it
Diagnostic detection
Roche’s Annual Report 2025 says its AI algorithms in Diagnostics sharpen disease detection. The statement does not say by how much, for which tests, or compared with which earlier method. Diagnostics is where AI claims can most readily be tested against performance measures such as sensitivity, specificity and agreement with a reference standard, so the absence of those numbers is more noticeable here than elsewhere. Until such figures are published, the claim is a direction of improvement rather than a size of one.
#1 Best Overall
Biological insight
The CEO letter says AI decodes complex biological connections faster. The 2025 annual review places a sequencing milestone alongside its AI statements, but it reports that milestone separately and does not credit AI with it. The two should be kept apart. The sequencing time is a company-reported result; the interpretive gain the CEO describes is not quantified anywhere in the cited material.
Targeted drug development
Roche’s argument is that AI supports more targeted drug development, and that this works better inside a group that also runs diagnostics. The statement is general. The material cited here does not name a specific drug programme or quantify a result, so it cannot be used to judge whether AI shortened development timelines or improved how candidates were selected.
Predictive glucose monitoring with Accu-Chek SmartGuide
The 2024 CEO letter says AI helps the predictive features of Accu-Chek SmartGuide detect dangerous blood-glucose fluctuations earlier, enabling people to take timely action. This is the most patient-facing example Roche gives, and the one with the most direct line to an outcome. It is still a company-reported example. The letter contains no comparative performance data and does not independently establish that users’ health improved.
Why Roche argues its group structure matters
Roche’s case rests on organisation as much as technology. Because diagnostics and pharmaceuticals sit inside one group, diagnostic information can connect with pharmaceutical research and treatment development. This is a claim about how the company is built and what it expects that to enable. Roche is the source of the argument, and the material does not measure whether the arrangement has produced faster development or better patient results. It should be read as a strategic argument, not a demonstrated result.
Rank #3
The changing-world argument Roche makes
Schinecker describes healthcare systems facing longer life expectancy, rising disease burden and rising costs. He also states that half the world’s population still lacks access to the most basic healthcare. That access figure is the CEO’s own statement in the 2024 letter. It is not an independently verified statistic, and it should be attributed to Roche when quoted.
The letter links Roche’s combined diagnostics and pharmaceuticals work to three disease areas that the company expects to account for almost 50% of global disease burden by 2035: cancer, cardiovascular-metabolic diseases and neurological diseases. This is a forward-looking company projection. It is neither an observed trend nor an independent forecast.
The 2024 annual review video narration frames the same case in general terms: “Today, patient needs are changing faster than ever. And as society, technology, politics and science evolve with incredible speed, so must healthcare.” The narrator is not named. The line is framing rather than evidence, and it supports the strategic context rather than any AI result.
Company figures and what they do not show
Roche’s 2025 annual review reports the figures below. None of them is attributed to AI, and they describe the company as a whole rather than the effect of any AI programme.
| Figure | Reported value | Attribution and qualifier |
|---|---|---|
| Group sales | CHF 61.5 billion in 2025 | Company-level figure, not attributed to AI. Roche reports growth rates at constant exchange rates unless otherwise stated. |
| Lives touched with high-medical-value diagnostics solutions | 258 million in 2025 | Company-level figure, not attributed to AI. |
| Human genome decoded by Roche’s next-generation sequencing technology | Less than four hours | Company-reported sequencing milestone. The source does not attribute it to AI. |
What evidence would change the picture
Roche’s published material supports a description of where it applies AI, not a measured account of what that AI has delivered. Evidence that would move these claims from company statement to demonstrated contribution would include:
- Published performance comparisons for the Diagnostics algorithms, showing detection results against the earlier method or a reference standard, with the test and patient population named.
- Independent evaluations of the Accu-Chek SmartGuide predictive alerts, including accuracy and whether users’ glucose outcomes changed after they acted on them.
- Named drug programmes where Roche attributes a specific development decision or timeline change to AI, with the comparison stated.
- Figures that Roche itself breaks out as AI-attributed, rather than presenting them alongside AI statements.
The company’s current strategy page and annual reports are the primary sources for each claim above, and readers should check them directly for updated figures.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Free tools Windows power users keep installed
One-click scans. No signup required.
